Novavax Future Growth

Future criteria checks 3/6

Novavax's revenue is forecast to decline at 16.1% per annum while its annual earnings are expected to grow at 76.8% per year. EPS is expected to grow by 78.1% per annum.

Key information

76.8%

Earnings growth rate

78.1%

EPS growth rate

Biotechs earnings growth28.3%
Revenue growth rate-16.1%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Sep 2024

Recent future growth updates

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Recent updates

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14
Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Sep 06
Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel

Earnings and Revenue Growth Forecasts

NasdaqGS:NVAX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202644035-8-863
12/31/2025490-1421-845
12/31/2024740-139-142-65
6/30/2024988-294-2414N/A
3/31/2024997-399-514-472N/A
12/31/2023984-545-773-714N/A
9/30/20231,050-549-727-655N/A
6/30/20231,597-587-737-654N/A
3/31/20231,359-1,155-753-653N/A
12/31/20221,982-658-509-416N/A
9/30/20221,847-1,322-728-641N/A
6/30/20221,291-1,476-814-744N/A
3/31/20221,403-1,318-489-429N/A
12/31/20211,146-1,744265323N/A
9/30/20211,204-1,075454537N/A
6/30/20211,182-950593672N/A
3/31/2021919-615575644N/A
12/31/2020476-418-97-43N/A
9/30/2020205-2734962N/A
6/30/202050-933237N/A
3/31/202018-115-110-109N/A
12/31/201919-133-138-137N/A
9/30/201916-150-160-158N/A
6/30/201921-177-162-159N/A
3/31/201929-182-171-169N/A
12/31/201834-185-186-185N/A
9/30/201839-186-184-183N/A
6/30/201839-186-196-194N/A
3/31/201835-186N/A-166N/A
12/31/201731-184N/A-144N/A
9/30/201726-190N/A-162N/A
6/30/201721-212N/A-181N/A
3/31/201717-247N/A-230N/A
12/31/201615-280N/A-259N/A
9/30/201616-302N/A-249N/A
6/30/201619-269N/A-215N/A
3/31/201631-210N/A-165N/A
12/31/201536-157N/A-126N/A
9/30/201537-110N/A-91N/A
6/30/201539-96N/A-78N/A
3/31/201533-94N/A-77N/A
12/31/201431-83N/A-67N/A
9/30/201433-65N/A-60N/A
6/30/201429-61N/A-59N/A
3/31/201425-56N/A-55N/A
12/31/201321-52N/A-45N/A
9/30/201317-46N/A-36N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: NVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: NVAX is expected to become profitable in the next 3 years.

Revenue vs Market: NVAX's revenue is expected to decline over the next 3 years (-16.1% per year).

High Growth Revenue: NVAX's revenue is forecast to decline over the next 3 years (-16.1% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NVAX's Return on Equity is forecast to be high in 3 years time


Discover growth companies